Patient enrolment completed for prevention of corneal transplant rejection trial - Ophthalmology Times Europe
Links shared publicly online about this topic.
- 2,160total visits
Patient enrolment completed for prevention of corneal transplant rejection trial - Ophthalmology Times Europe
Lux Biosciences has just completed its enrolment in the company's Phase III LUCIDA (LUx Corneal Transplant Implant Development and Advancement of Therapy) clinical trial programme for LUMITECT (LX201), a silicone matrix ocular (episcleral) implant designed to provide the continuous release for one year of therapeutic levels of cyclosporine A locally to the eye to prevent corneal transplant rejection.
View full resource at oteurope.com
Tags: Eye, Clinical Trial, Ophthalmology, Transplantation
Most Recently Shared on March 27, 2009 at 8:50 am By:
Patient enrolment completed for trial assessing implant for prevention of corneal transplant rejection. http://ow.ly/1sdq
Advertisement
